Qingyuan Zhang

Publication Activity (10 Years)

Years Active: 2019-2022
Publications (10 Years): 5

Top Topics

Signaling Pathway

Immune Response

Positive Breast Cancer

Top Venues

Disease markers

Cell death & disease

This page only lists publications with an associated author ORCID identifier.

Publications

Xingjian Niu, Lei Yin, Xudong Yang, Yue Yang, Yucui Gu, Yutian Sun, Ming Yang, Yiran Wang, Qingyuan Zhang, Hongfei Ji
Serum amyloid A 1 induces suppressive neutrophils through the Toll-like receptor 2-mediated signaling pathway to promote progression of breast cancer. Cancer science 113 (4) (2022)
Han Zhang, Jinlu Wang, Jingtong Li, Xiaoping Zhou, Lei Yin, Yiran Wang, Yucui Gu, Xingjian Niu, Yue Yang, Hongfei Ji, Qingyuan Zhang
HMGB1 is a key factor for tamoxifen resistance and has the potential to predict the efficacy of CDK4/6 inhibitors in breast cancer. Cancer science 112 (4) (2021)
Xingjian Niu, Jianli Ma, Jingtong Li, Yucui Gu, Lei Yin, Yiran Wang, Xiaoping Zhou, Jinlu Wang, Hongfei Ji, Qingyuan Zhang
Sodium/glucose cotransporter 1-dependent metabolic alterations induce tamoxifen resistance in breast cancer by promoting macrophage M2 polarization. Cell death & disease 12 (6) (2021)
Jinlu Wang, Hongfei Ji, Xingjian Niu, Lei Yin, Yiran Wang, Yucui Gu, Dongbo Li, Han Zhang, Minghui Lu, Fengxia Zhang, Qingyuan Zhang
Sodium-Dependent Glucose Transporter 1 (SGLT1) Stabled by HER2 Promotes Breast Cancer Cell Proliferation by Activation of the PI3K/Akt/mTOR Signaling Pathway in HER2+ Breast Cancer. Disease markers 2020 (2020)
Dongbo Li, Hongfei Ji, Xingjian Niu, Lei Yin, Yiran Wang, Yucui Gu, Jinlu Wang, Xiaoping Zhou, Han Zhang, Qingyuan Zhang
Tumor-associated macrophages secrete CC-chemokine ligand 2 and induce tamoxifen resistance by activating PI3K/Akt/mTOR in breast cancer. Cancer science 111 (1) (2019)